Sera Prognostics, Inc. (SERA) stock
SERANasdaqServices-Medical LaboratoriesFiscal year ends December 31
$2.01+0.03 (+1.52%)
Close on Nov 13, 2026Market cap $79.29MP/E –Yield –
Sera Prognostics r&d expenses
Research and development expenses are spending on new products and technology.
Sera Prognostics's R&D Expenses for the twelve months ending Sep 30, 2026 was $12.46M, down 4.8% year over year. For fiscal 2025 it was $13.17M, down 10.6% from the year before. The highest annual figure on record is $15.23M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.17M | -10.6% |
| FY2024 | Dec 31, 2024 | $14.73M | -3.3% |
| FY2023 | Dec 31, 2023 | $15.23M | +6.9% |
| FY2022 | Dec 31, 2022 | $14.24M | +29.3% |
| FY2021 | Dec 31, 2021 | $11.02M | +41.6% |
| FY2020 | Dec 31, 2020 | $7.78M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.72M | -17.1% |
| Q2 FY2026 | Jun 30, 2026 | $3.49M | +4.7% |
| Q1 FY2026 | Mar 31, 2026 | $3.03M | -9.1% |
| Q4 FY2025 | Dec 31, 2025 | $3.22M | +2.5% |
| Q3 FY2025 | Sep 30, 2025 | $3.28M | -6.2% |
| Q2 FY2025 | Jun 30, 2025 | $3.34M | -24.3% |
| Q1 FY2025 | Mar 31, 2025 | $3.33M | -9.5% |
| Q4 FY2024 | Dec 31, 2024 | $3.14M | -19.4% |
| Q3 FY2024 | Sep 30, 2024 | $3.50M | -1.0% |
| Q2 FY2024 | Jun 30, 2024 | $4.41M | +19.5% |
| Q1 FY2024 | Mar 31, 2024 | $3.68M | -10.2% |
| Q4 FY2023 | Dec 31, 2023 | $3.90M | +11.8% |
| Q3 FY2023 | Sep 30, 2023 | $3.54M | -15.3% |
| Q2 FY2023 | Jun 30, 2023 | $3.69M | +13.1% |
| Q1 FY2023 | Mar 31, 2023 | $4.10M | +23.5% |
| Q4 FY2022 | Dec 31, 2022 | $3.49M | +13.3% |
| Q3 FY2022 | Sep 30, 2022 | $4.18M | +53.3% |
| Q2 FY2022 | Jun 30, 2022 | $3.26M | +15.5% |
| Q1 FY2022 | Mar 31, 2022 | $3.32M | +38.6% |
| Q4 FY2021 | Dec 31, 2021 | $3.08M | +47.0% |
| Q3 FY2021 | Sep 30, 2021 | $2.72M | +44.3% |
| Q2 FY2021 | Jun 30, 2021 | $2.82M | +61.2% |
| Q1 FY2021 | Mar 31, 2021 | $2.40M | – |
| Q4 FY2020 | Dec 31, 2020 | $2.09M | – |
| Q3 FY2020 | Sep 30, 2020 | $1.89M | – |
| Q2 FY2020 | Jun 30, 2020 | $1.75M | – |
See a number that looks wrong?